Novartis Agrees to Trim Drug Prices in US Amid Investment Push

01:45 AM EST, 12/21/2025 (MT Newswires) -- Novartis (NOVN.SW) has struck a deal with the US administration to reduce the price of innovative medicines in the country, following a $23 billion investment commitment made earlier in 2025. In line with the US government's drug pricing priorities, the Swiss drugmaker will roll out future medicines with prices comparable to high-income countries and create direct-to-patient platforms for sclerosis medication Mayzent and cancer drugs Rydapt and Tabrecta using the TrumpRx website, according to a Dec. 19 release. Novartis will also participate in the GENEROUS Model, which targets further access to medicines in the US Medicaid program.